Antiretroviral treatment of HIV infection: Swedish recommendations 2005

References

• Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, 3rd, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350: 1850–61
   PubMed Web of Science ®Google Scholar
• Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039–46
   PubMed Web of Science ®Google Scholar
• DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39: 1038–46
   PubMed Web of Science ®Google Scholar
• Gallant, J, Rodriguez, A, Weinberg, W. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. In:. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2003. Chicago, IL.
   Google Scholar
• Leon A, Martinez E, Mallolas J, Laguno M, Blanco JL, Pumarola T, et al. Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. Aids 2005; 19: 213–5
   PubMed Web of Science ®Google Scholar
• Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, et al. Comparison of sequential 3-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349: 2293–303
   PubMed Web of Science ®Google Scholar
• Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35: 538–9
   PubMed Web of Science ®Google Scholar
• Wood R, Phanuphak P, Cahn P, Pokrovskiy V, Rozenbaum W, Pantaleo G, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004; 36: 684–92
   PubMed Web of Science ®Google Scholar
• Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005; 40: 594–600
   PubMed Web of Science ®Google Scholar
• Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. Aids 2005; 19: 63–7
   PubMed Web of Science ®Google Scholar
• Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, et al. Intermittent HIV-1 viraemia (Blips) and drug resistance in patients receiving HAART. Jama 2005; 293: 817–29
   PubMed Web of Science ®Google Scholar
• Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9: 829–48
   PubMed Web of Science ®Google Scholar
• Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, et al. Impact of therapeutic immunization on HIV-1 viraemia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005; 192: 607–17
   PubMed Web of Science ®Google Scholar
• Bang, LM, Scott, LJ. Emtricitabine: an antiretroviral agent for HIV infection. Drugs 2003; 63:2413–24; discussion 2425–6.
   PubMed Web of Science ®Google Scholar
• Piketty, C, Pellegrin, I, Katlama, C. Efficacy of tenofovir fumarate in hepatits B virus in HIV coinfected pateints: the TECOVIR study. In:. 11th Conference on Retrovirus and Opportunistic Infections. 2004. San Francisco, CA.
   Google Scholar
• Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302–6
   PubMed Web of Science ®Google Scholar
• Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292–7
   PubMed Web of Science ®Google Scholar
• Vallet-Pichard A, Pol S. Hepatitis viruses and human immunodeficiency virus coinfection: pathogenesis and treatment. J Hepatol 2004; 41: 156–66
   PubMedGoogle Scholar
• Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, et al. Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an HIV-HBV International Panel. Aids 2005; 19: 221–40
   PubMed Web of Science ®Google Scholar
• Benhamou, Y, Thibault, V, Vig, P. Long-term treatment with adefovir dipivoxil 10 mg (ADV) in patients with lamivudine resistant (LAM-R) HBV and HIV coinfection results in significant and sustained clinical improvement. In:. 15th International Conference of AIDS. 2004. Bangkok, Thailand.
   Google Scholar
• Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185–92
   PubMed Web of Science ®Google Scholar
• Bani-Sadr F, Palmer P, Scieux C, Molina JM. 96-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis 2004; 39: 1062–4
   PubMed Web of Science ®Google Scholar
• Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000; 18: 1161–5
   PubMed Web of Science ®Google Scholar
• Kewn S, Hoggard PG, Henry-Mowatt JS, Veal GJ, Sales SD, Barry MG, et al. Intracellular activation of 2′,3′-dideoxyinosine and drug interactions in vitro. AIDS Res Hum Retroviruses 1999; 15: 793–802
   PubMedGoogle Scholar
• EMEA Public Statement. Important new pharmacokinetic data demonstrating that REYATAZ (atazanavir sulfate) combined with NORVIR (ritonavir) and omeprazole should not be co-administered. p. www.emea.eu.int/pdfs/human/press/pus/20234904en.pdf.
   Google Scholar
• Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's Wort. Lancet 2000; 355: 547–8
   PubMed Web of Science ®Google Scholar
• Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, et al. Reversibility of lipoatrophy in HIV-infected patients 2 y after switching from a thymidine analogue to abacavir: the MITOX Extension Study. Aids 2004; 18: 1029–36
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993–2003
   PubMed Web of Science ®Google Scholar